Oculis S.A.
https://oculis.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oculis S.A.
Oculis Eyes Success In Wide Range Of Ophthalmic Conditions
Oculis has enjoyed a strong first six months of 2023 after demonstrating the potential of OCS-01 to treat a variety of eye conditions and establishing a presence in the US.
Oculis Eyes Double DIAMOND After Initial Phase III Success In DME
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.
NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice